Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103311 · ClinicalTrials.gov registry record · Phase 2
SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT00103311: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00103311 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00103311, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying how well SB-715992 works in treating patients with advanced or metastatic colorectal cancer. Drugs used in chemotherapy, such as SB-715992, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Interventions
- OTHER laboratory biomarker analysis
- DRUG ispinesib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2005-01 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00103311
The ClinicalTrials.gov registry entry for NCT00103311 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00103311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00103311 about?
NCT00103311 is a clinical study titled "SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer". This randomized phase II trial is studying how well SB-715992 works in treating patients with advanced or metastatic colorectal cancer. Drugs used in chemotherapy, such as SB-715992, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividi...
What is the current status of trial NCT00103311?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2005-01. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00103311?
The interventions under investigation include: laboratory biomarker analysis (OTHER), ispinesib (DRUG).
Who is sponsoring clinical trial NCT00103311?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.